Keywords
Intracranial Pressure
Mannitol
Hypertonic Saline Solution
Complications
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To compare the most prevalent complications in the use of hyperosmolar solutions (mannitol and hypertonic saline solution (HSS) in the management of intracranial hypertension (ICH). Literature review: Elevated intracranial pressure (ICP) is an important predictor of neurological deterioration and many studies have compared the effectiveness of hyperosmolar therapies in controlling cranial hypertension, the most studied being hypertonic saline solution and mannitol. This article discusses the intercurrences of these two solutions during their administration in the management of ICH, in order to verify if one of them has less adverse effect compared to the other and if there are specific situations in which the use of each one is better suited. Conclusion: It is observed that, in addition to the similar benefits documented in the literature regarding the use of mannitol and HSS in the management of ICH, there are also similar complications such as AKI and the rebound effect. In this sense, the present study aims to compare the common intercurrences and the others with the objective of clarifying a detailed analysis of these effects for the choice of agent and more effective management of patients.
References
BENSON JC, et al. The Monro-Kellie Doctrine: A Review and Call for Revision. American Journal of Neuroradiology. 2023; 44(1): 2-6.
COOK AM, et al. Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients. Neurocrit Care. 2020; 32(3): 647-666.
CHEN H, et al. Hypertonic saline versus other intracranial pressure-lowering agents for people with acute traumatic brain injury. Cochrane Database Syst Rev. 2019; 12(12): CD010904.
CHESANI FH, et al. O uso dos critérios de diagnóstico da síndrome do desconforto respiratório agudo por profissionais da saúde para pacientes internados em UTI: um estudo observacional utilizando a técnica de análise de conteúdo. Rev. Assoc. Méd. Rio Gd. do Sul. 2019; 4: 65.
DEVEAU RF Jr, et al. Safety of peripherally administered 3% hypertonic saline. Am J Emerg Med. 2023; 63: 127-131.
ERDMAN MJ,et al. Predictors of Acute Kidney Injury in Neurocritical Care Patients Receiving Continuous Hypertonic Saline. Neurohospitalist. 2017; 7(1): 9-14.
FANG J, et al. Comparison of equiosmolar hypertonic saline and mannitol for brain relaxation during craniotomies: A meta-analysis of randomized controlled trials. Neurosurg Rev. 2018; 41(4): 945-956.
FLORIDO LMP, et al. Hipertensão intracraniana no TCE: Solução salina hipertônica vs. Manitol. Revista Caderno de Medicina. 2019; 2(3): 5-12.
FURQUIM JD, et al. Manejo da hipertensão intracraniana no trauma cranioencefálico pediátrico. Residência Pediatrica. 2022; 12(3): 632-640.
GONDIM FAA, et al. Osmolality not predictive of mannitol-induced acute renal insufficiency. J Neurosurg. 2005; 103(3): 444-7.
GU J, et al. Hypertonic saline or mannitol for treating elevated intracranial pressure in traumatic brain injury: a meta-analysis of randomized controlled trials. Neurosurg Rev. 2019; 42: 499–509.
GONDA DD, et al. Complications associated with prolonged hypertonic saline therapy in children with elevated intracranial pressure. Pediatr Crit Care Med. 2013; 14(6): 610-20.
HALSTEAD MR, GEOCADIN RG. The Medical Management of Cerebral Edema: Past, Present, and Future Therapies. Neurotherapeutics. 2019; 16(4): 1133-1148.
HUANG X, et al. Equimolar doses of hypertonic agents (saline or mannitol) in the treatment of intracranial hypertension after severe traumatic brain injury. Medicine (Baltimore). 2020; 99(38): e22004.
JAGANNATHA AT, et al. An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. J Clin Neurosci. 2016; 27: 68-73.
JANNOTTA GE, et al. Administration of 3% Sodium Chloride Through Peripheral Intravenous Access: Development and Implementation of a Protocol for Clinical Practice. Worldviews Evid Based Nurs. 2021; 18(2): 147-153.
MANGAT HS. Hypertonic saline infusion for treating intracranial hypertension after severe traumatic brain injury. Crit Care. 2018; 22(1): 37.
MANGAT HS, et al. Hypertonic Saline is Superior to Mannitol for the Combined Effect on Intracranial Pressure and Cerebral Perfusion Pressure Burdens in Patients With Severe Traumatic Brain Injury. Neurosurgery. 2020; 86(2): 221-230.
MIYOSHI Y, et al. Effects of hypertonic saline versus mannitol in patients with traumatic brain injury in prehospital, emergency department, and intensive care unit settings: a systematic review and meta-analysis. j intensive care. 2020; 8: 61.
MUSSI HG, et al. Métodos não invasivos para monitorização da pressão intracraniana: uma revisão atual. Revista Eletrônica Acervo Saúde. 2023. 23(1): e11450.
PEREZ CA, FIGUEROA SA. Complication Rates of 3% Hypertonic Saline Infusion Through Peripheral Intravenous Access. Journal of Neuroscience Nursing, 2017; 49(3):191-195.
POOLE D, et al. Evidence for Mannitol as an Effective Agent Against Intracranial Hypertension: An Individual Patient Data Meta-analysis. Neurocrit Care. 2020; 32(1): 252-261.
RAY PK, et al. Study of changes in cardiac output, stroke volume, and cardiac index with two doses of mannitol infusion during supratentorial craniotomy. Ain-Shams J Anesthesiol. 2022; 14: 94-101.
ROQUILLY A, et al. Effect of Continuous Infusion of Hypertonic Saline vs Standard Care on 6-Month Neurological Outcomes in Patients With Traumatic Brain Injury: The COBI Randomized Clinical Trial. JAMA. 2021; 325(20): 2056-2066.
SEO H, et al. A prospective randomized trial of the optimal dose of mannitol for intraoperative brain relaxation in patients undergoing craniotomy for supratentorial brain tumor resection. J Neurosurg. 2017; 126(6): 1839-1846.
SHI J, et al. Hypertonic saline and mannitol in patients with traumatic brain injury: A systematic and meta-analysis. Medicine (Baltimore). 2020; 99(35): e21655.
SU Y, et al. Comparison of equiosmolar doses of 10% hypertonic saline and 20% mannitol for controlling intracranial hypertention in patients with large hemispheric infarction. Clin Neurol Neurosurg. 2021; 200: 106359.
TSAOUSI G, et al. Cardiac output changes after osmotic therapy in neurosurgical and neurocritical care patients: a systematic review of the clinical literature. Br J Clin Pharmacol. 2018; 84(4): 636-648.
WEBSTER DL, et al. Higher-volume hypertonic saline and increased thrombotic risk in pediatric traumatic brain injury. J Crit Care. 2015; 30(6): 1267-71.
WIÓREK A, et al. Hyperosmolar Treatment for Patients at Risk for Increased Intracranial Pressure: A Single-Center Cohort Study. Int J Environ Res Public Health. 2020; 17(12): 4573.
WITHERSPOON B, ASHBY NE. The Use of Mannitol and Hypertonic Saline Therapies in Patients with Elevated Intracranial Pressure: A Review of the Evidence. Nurs Clin North Am. 2017; 52(2): 249-260.
ZHANG W, et al. Mannitol in Critical Care and Surgery Over 50+ Years: A Systematic Review of Randomized Controlled Trials and Complications With Meta-Analysis. J Neurosurg Anesthesiol. 2019; 31(3): 273-284.